Presidio Pharmaceuticals Licenses Nuclear Exclusion Compounds From Cytokine PharmaSciences

SAN FRANCISCO & KING OF PRUSSIA, Pa.--(BUSINESS WIRE)--Presidio Pharmaceuticals, Inc. and Cytokine PharmaSciences, Inc. announced today that Presidio has licensed from Cytokine PharmaSciences the rights to a series of preclinical-stage compounds for treatment of HIV-1 infection. The agreement also includes the Nuclear Exclusion Technology (NEXT™), which allows treatment of HIV-1 infection and other viruses via inhibition of nuclear importation. Details of the agreement were not disclosed.